The invention provides the use of an antagonist of CXCL 13 or CXCR5 activity in the preparation of a medicament for the prevention and/or inhibition of pathological scarring; as well as the use of such antagonists in the preparation of a medicament for the prevention and/or inhibition of fibrotic disorders; and the use of such antagonists in the preparation of a medicament for the prevention and/or treatment of a chronic wound. Medicaments or methods of the invention are particularly suitable for use in keloids or venous ulcers. Suitable antagonists of CXCL13 or CXCR5 activity may be any compound capable of inhibiting the CXCL13/CXCR5 signalling pathway. The invention also provides a model of aberrant wound healing, which may lead to pathological scar formation, or to chronic wound formation.